9 Aug 2012: Cai R, Liu Z, Ren J, Ma C, Gao T, et al. (2012) Correction: GPS-MBA: Computational Analysis of MHC Class II Epitopes in Type 1 Diabetes. PLOS ONE 7(8): 10.1371/annotation/97a13c7b-1037-4293-bf15-be18d0550f0c. https://doi.org/10.1371/annotation/97a13c7b-1037-4293-bf15-be18d0550f0c View correction
As a severe chronic metabolic disease and autoimmune disorder, type 1 diabetes (T1D) affects millions of people world-wide. Recent advances in antigen-based immunotherapy have provided a great opportunity for further treating T1D with a high degree of selectivity. It is reported that MHC class II I-Ag7 in the non-obese diabetic (NOD) mouse and human HLA-DQ8 are strongly linked to susceptibility to T1D. Thus, the identification of new I-Ag7 and HLA-DQ8 epitopes would be of great help to further experimental and biomedical manipulation efforts. In this study, a novel GPS-MBA (MHC Binding Analyzer) software package was developed for the prediction of I-Ag7 and HLA-DQ8 epitopes. Using experimentally identified epitopes as the training data sets, a previously developed GPS (Group-based Prediction System) algorithm was adopted and improved. By extensive evaluation and comparison, the GPS-MBA performance was found to be much better than other tools of this type. With this powerful tool, we predicted a number of potentially new I-Ag7 and HLA-DQ8 epitopes. Furthermore, we designed a T1D epitope database (TEDB) for all of the experimentally identified and predicted T1D-associated epitopes. Taken together, this computational prediction result and analysis provides a starting point for further experimental considerations, and GPS-MBA is demonstrated to be a useful tool for generating starting information for experimentalists. The GPS-MBA is freely accessible for academic researchers at: http://mba.biocuckoo.org.
Citation: Cai R, Liu Z, Ren J, Ma C, Gao T, Zhou Y, et al. (2012) GPS-MBA: Computational Analysis of MHC Class II Epitopes in Type 1 Diabetes. PLoS ONE 7(3): e33884. https://doi.org/10.1371/journal.pone.0033884
Editor: Lukasz Kurgan, University of Alberta, Canada
Received: November 26, 2011; Accepted: February 18, 2012; Published: March 27, 2012
Copyright: © 2012 Cai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported, in whole or in part, by the National Basic Research Program (973 project) (2010CB945400, 2012CB911200,2012CB910101), the Natural Science Foundation of China (90919001, 31071154, 30900835, 30830036, 91019020, 31171263) and by the Fundamental Research Funds for the Central Universities (HUST: 2010JC049, 2010ZD018, 2011TS085; SYSU: 11lgzd11). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Type 1 diabetes (Diabetes mellitus type 1, T1D or T1DM) is a severe chronic autoimmune disease with a relapsing-remitting course that is characterized by the insidious loss of self-tolerance and progressive destruction of insulin-producing pancreatic β-cells in the islets of Langerhans, with the presence of overt hyperglycemia at the time of clinical diagnosis –. The incidence and prevalence of T1D has dramatically increased worldwide over the past several decades, and the onset and development of T1D is believed to be controlled by both genetic and environmental factors –, . The cumulative analysis has revealed that a variety of immune cell types, including CD4+, CD8+ T cells, macrophages and dendritic cells (DCs) are involved in β-cell death, and CD4+ T cells play the predominant role in the overall T1D pathology , , . Thus, the development of immunoregulatory therapeutic approaches has come to be an urgent demand for preventing, treating or even curing T1D –.
Besides immunosuppressive drugs and antibody-based immunotherapies, antigen-based “tolerogenic” immunotherapy has attracted considerable attention as a third-generation approach, particularly for its highly selective targeting of aberrant T cells –. It was demonstrated that the MHC class II haplotype, I-Ag7, is strongly linked to susceptibility to T1D in the non-obese diabetic (NOD) mouse –. Similar linkage to the human HLA-DQ8 molecule, I-Ag7 is expressed by DCs to present β-cell epitopes from certain well-defined autoantigens, including insulin, glutamic acid decarboxylase (GAD) and insulinoma antigen 2 (IA-2) –, . These epitopes are usually composed of 10 to 30 amino acids, with a 9-amino acid core sequence for I-Ag7/HLA-DQ8 and T-cell receptor (TCR) binding –. In this regard, identification of I-Ag7/HLA-DQ8 epitopes is fundamental for an understanding of the molecular mechanisms of T1D and the improved design of immunotherapeutic peptides. In 2009, the first-in-human beings Phase I clinical study reported that proinsulin peptide injection is both well tolerated and safe . Recently, a C-peptide deduced from the GAD 65 isoform has generated promising results in Phase II trials, and three Phase III trials are still ongoing , , .
As a complement to labor-intensive and time-consuming experimental assays, the in silico prediction of MHC-binding epitopes has emerged as an efficient approach to generate useful information for the purposes of biomedical design ,  (see also http://mba.biocuckoo.org/ links.php). For example, the prediction results of SYFPEITHI  and BIMAS  were successfully used for the experimental identification of novel MHC class I epitopes derived from type 1 diabetes autoantigens –. Since I-Ag7 is the only expressed MHC class II molecule in the NOD mouse , , additional efforts have subsequently been expended on the prediction of I-Ag7 or HLA-DQ8 epitopes –. In 2006, Rajapakse et al. developed the first online server of PREDNOD for the prediction of I-Ag7, and the two MHC class I molecules Kd and Db binding peptides in the NOD mouse . They subsequently refined the predictor using multi-objective evolutionary algorithms (MOEA) . Chang et al. used an expectation-maximization alignment algorithm to design computational programs for the prediction of I-Ag7  and HLA-DQ8  epitopes, respectively. Furthermore, the two integrative tools of MHC2Pred ,  and RANKPEP  also include predictors for I-Ag7 and HLA-DQ8, although they were developed for the comprehensive prediction of a variety of MHC class I and/or II binding peptides. Currently, although a number of computational studies have been performed, only MHC2Pred ,  and RANKPEP  are accessible over the internet.
In this work, we developed a novel GPS-MBA software package for the prediction of I-Ag7 and HLA-DQ8. The experimentally identified epitopes were obtained from the scientific literature, and a modified Gibbs sampling approach was adopted to determine the core nonamers in these epitopes. For training and prediction, a refined GPS algorithm ,  was used. By extensive evaluation and comparison, the prediction performance of GPS-MBA was shown to be highly promising and much better than the other tools currently in use. Moreover, by cross-evaluation using the HLA-DQ8 predictor in GPS-MBA to predict the I-Ag7 epitopes and vice versa, the results show that I-Ag7 and HLA-DQ8 recognize highly similar peptide profiles. With this powerful tool, we predicted potentially novel I-Ag7 and HLA-DQ8 binding peptides from T1D-associated epitopes, which bind to other types of MHC molecules. All of the experimentally identified T1D antigens together with their epitopes were absorbed into TEDB 1.0. The ab initio predicted epitopes were also provided. Taken together, the prediction and analysis results are helpful for further experimental investigation, and the GPS-MBA can serve as a practically useful adjunct program for experimentalists. The online service and local packages of GPS-MBA 1.0 were implemented in JAVA and freely accessible for academic research purposes at: http://mba.biocuckoo.org.
A search of the scientific literature from PubMed (before Sept. 20th, 2011) with the keywords “I-Ag7 peptide”, “HLA-DQ8 peptide”, or “Type 1 diabetes epitope”, we collected 318 experimentally verified and naturally processed mouse I-Ag7 binding peptides in 177 proteins, and 134 human HLA-DQ8 epitopes from 84 proteins (Table 1). Additional keywords were tried, but the data set was not changed. The protein sequences were retrieved from the UniProt database (http://www.uniprot.org/uniprot/).
In our data set, the length of most of the epitopes varies from 9∼30aa. Thus, we adopted a refined Gibbs sampling approach ,  to determine the 9aa core peptides, and obtained 301 unique nonamer epitopes for the I-Ag7 and 127 HLA-DQ8 core peptides for training. We also prepared positive (+) and negative (−) data sets for testing. The 318 I-Ag7 and 134 HLA-DQ8 epitopes of known length were regarded as the (+) set. If at least one predicted nonamer is fully located in the epitope region, the epitope is predicted as a positive hit. To avoid any bias, all of the 9-mer lengths of the same proteins which were either not covered or not fully covered by the original epitopes were taken to be the (−) set.
By further literature review, we collected 203 T1D-associated epitopes in 25 proteins which have the potential to be recognized by other types of MHC or unknown molecules (Table 1).
As previously described , , we used the four measurements of sensitivity (Sn), specificity (Sp), accuracy (Ac) and Mathew's Correlation Coefficient (MCC). The measurements were defined as below:and
To evaluate the prediction performance and robustness, the leave-one-out (LOO) validation and 4-, 6-, 8- and 10-fold (n-fold) cross-validations were performed. In the LOO validation, each core nonamer in the data set was picked out in turn as an independent test sample, and all the remaining core nonamers were regarded as training data. This process was repeated until each nonamer was used as test data one time. In the n-fold cross-validation, all the (+) core nonamers and (−) nonamers were mixed and then divided equally into n parts, keeping the same distribution of (+) and (−) nonamers in each part. Then n-1 parts were merged into a training data set while the remnant part was taken as a testing data set. This process was repeated 20 times and the average performance of n-fold cross-validation was computed. Furthermore, the Receiver Operating Characteristic (ROC) curves were drawn, and AROC (area under ROC) values were calculated.
Previously, we developed a series of GPS algorithms for the prediction of post-translational modification (PTM) sites in proteins , . For the prediction of the I-Ag7 and HLA-DQ8 binding peptides, we used the original method to develop a new algorithm containing two computational parts, a scoring strategy and performance improvement.
The basic hypothesis behind the scoring strategy is that similarly short peptides would exhibit similar 3D structures and biochemical properties , . Thus, we can directly use an amino acid substitution matrix, e.g., BLOSUM62, to calculate the similarity between two 9-mer peptides A and B as:
Score(A[i], B[i]) denotes the substitution score of the two amino acids of A[i] and B[i] in the BLOSUM62 at the position i. If S(A, B)<0, we redefined it as S(A, B) = 0. A given nonapeptide is then compared with each of the 9aa core peptides from the training data in a pairwise manner to calculate the similarity score. The average value of the substitution scores is regarded as the final score.
The performance improvement procedure is comprised of two steps, weight training (WT) and matrix mutation (MaM). To evaluate the degree of performance improvement, we calculated the scores for all sites of the training data set in each time. By gradually increasing the threshold, we computed the Sn, Sp, Ac and MCC under different cut-off values. Thus, we fixed the Sp at 90% and compared the Sn values of the LOO validation.
1) Weight training (WT).
Initially, the weight of each position was defined as 1. The wi value is the weight of the position i. Again, if S′(A, B) is <0, we redefined it as S′(A, B) = 0. Then we randomly picked out the weight of any position for +1 or −1 and re-computed the LOO result. The manipulation was adopted if the Sn value was increased. This process was continued until the Sn value did not increase any further.
2) Matrix mutation (MaM).
The aim of this step is to generate an optimal or near-optimal scoring matrix from an initial matrix. We re-calculated the LOO result to improve the Sn value by randomly picking out an element of the BLOSUM62 matrix for +1 or −1. The process was repeated until convergence was reached. Selecting a different initial matrix, e.g., BLOSUM45 will generate a convergent result if the training time is sufficient (Data not shown).
Implementation of the online service and local packages
The online service and local packages of GPS-MBA 1.0 were implemented in JAVA. For the online service, we tested GPS-MBA 1.0 on a variety of internet browsers, including Internet Explorer 6.0, 8.0 and 9.0, Mozilla Firefox 8.0 and Google Chrome under the Windows XP and Windows 7 Operating System (OS), Mozilla Firefox 8.0 and Google Chrome under Fedora Core 15 and Ubuntu 10.04 LTS (Linux), and Safari 5.1.1 under Apple Mac OS ×10.5 (Leopard) and 10.7 (Lion). For the Windows and Linux systems, the latest version of Java Runtime Environment (JRE) package (Java SE 5.0 or later versions) should be pre-installed. However, for Mac OS, GPS-MBA 1.0 can be directly used without any additional packages. For convenience, we also developed local packages of GPS-MBA 1.0 which support the three major Operating Systems Windows, Linux and Mac OS X.
Determination of the core nonamers from the I-Ag7 and HLA-DQ8 epitopes
From the scientific literature, we collected 318 naturally processed I-Ag7 epitopes and 134 HLA-DQ8 binding peptides of various lengths from 8∼30aa (Table 1). The prerequisite for the usage of GPS algorithm is that the length of peptides must be fixed and identical in the training data set , . Previously, experimental analyses had suggested that the I-Ag7 and HLA-DQ8 epitopes contain the 9aa core sequences needed for recognition and binding –. Since there is only one epitope with 8aa, we added one residue upstream and one residue downstream for the 8aa peptide so as to form a decapeptide. Then we used an adapted Gibbs sampling approach to determine the core nonamers of the I-Ag7 (Table S1) and HLA-DQ8 epitopes (Table S2) –.
Given a set of N epitopes S1, …, SN, we sought to identify the most probable nonapeptides that were mutually present in both epitopes (Figure 1). First, one 9-mer length per epitope as P1, …, PN was randomly selected, while we randomly singled out one epitope Si together with its nonapeptide Pi (Figure 1). Then we calculated the similarity scores for all of the 9-mer peptides sequentially in Si, as described below:
The Score(Pi) is the average final similarity score compared with the other nonamers, while S(Pi, Pj) is the similarity score between Pi and Pj. The 9-mer with the maximal Score(Pi) is sampled and then updated to the new nonapeptide Pi (Figure 1). Such a sampling procedure was iteratively repeated until convergence was attained (Figure 1). Ultimately, the redundant 9-mer core peptides were made clearly evident (Table 1, Table S1 and S2).
Development of GPS-MBA for the prediction of I-Ag7 and HLA-DQ8 binding peptides
The series of GPS algorithms contain two computational procedures of a scoring strategy and performance improvement , . The scoring step has remained the same in all the versions of the GPS algorithms, while the latter process is still in the process of being improved for better performance , . In the latest GPS 3.0 release, the performance improvement procedure is comprised of the four sequential steps of k-means clustering, motif length selection (MLS), WT and MaM . Originally, we proposed that such a training order could not be changed , whereas our recent analysis instead suggests that such an order can be shuffled if the training time is sufficient (Data not shown).
When the training data set is large, the k-means clustering approach can be used to classify positive data into multiple groups . However, due to limited data available, this method was not used in this work. The MLS approach was designed for determining the motif length for optimal performance . Since experimental studies suggest that the nonamer core peptides are essential for I-Ag7 and HLA-DQ8 recognition –, this strategy was also not adopted.
Taken together, the GPS algorithm has been improved, and the performance improvement process only required the two steps of WT and MaM. The training order was shuffled for better performance, and the online service and software packages of GPS-MBA 1.0 were implemented in JAVA. As an example, the prediction results for the mouse Igκ chain C region (UniProt ID: P01837) are shown (Figure 2). Previously, a peptide in the mouse Igκ L chain (174ERQNGVLNSWTDQDS188, identical to 46–60 in the Igκ chain C region) was sequenced as an I-Ag7 epitope by MS/MS analysis . In our results, four potential I-Ag7 epitopes of 4APTVSIFPP12, 49NGVLNSWTD57, 68SSTLTLTKD76, and 69STLTLTKDE77 were predicted (Figure 2). The 49NGVLNSWTD57 nonamer gives complete coverage of the experimental epitope (46–60), while the other three predicted hits are available for further experimental investigation.
Performance evaluation and comparison
To evaluate the prediction performance and robustness of GPS-MBA, LOO validation and 4-, 6-, 8-, 10-fold cross-validations were performed (Figure 3A, 3B). ROC curves were drawn, while the AROC values were 0.909 (LOO), 0.909 (4-fold), 0.904 (6-fold), 0.916 (8-fold) and 0.919 (10-fold) for mouse I-Ag7 (Figure 3A), and 0.921 (LOO), 0.933 (4-fold), 0.928 (6-fold), 0.937 (8-fold) and 0.931 (10-fold) for human HLA-DQ8 (Figure 3B). Since the results of the 4-, 6-, 8- and 10-fold cross-validations were closely similar to the LOO validation, the GPS-MBA 1.0 is evidently a stable and robust predictor. The performance of the LOO validation was also used for the cut-off setting and further comparison, and the three thresholds of high, medium and low were selected with the Sp values of 97%, 95% and 90%, respectively (Table 2). In addition, given the highest MCC values, the medium thresholds were chosen as the default thresholds of I-Ag7 (0.1541) and HLA-DQ8 (0.1534), respectively (Table 2).
The LOO validation and 4-, 6-, 8- and 10-fold cross-validations were performed for (A) mouse I-Ag7 and (B) human HLA-DQ8, respectively. We compared the performance of GPS-MBA 1.0 with MHC2Pred and RANKPEP using the LOO validation for (C) I-Ag7 and (D) HLA-DQ8, respectively. We also performed a cross-evaluation by using the HLA-DQ8 predictor in GPS-MBA to predict (C) I-Ag7 epitopes and (D) vice versa.
To clearly demonstrate the superiority of GPS-MBA, we also used the same data sets to evaluate the performances of MHC2Pred ,  and RANKPEP . We fixed the Sp values of MHC2Pred and RANKPEP so as to be similar to GPS-MBA and compared the Sn values (Table 2). For I-Ag7, when the Sp value was ∼97%, the Sn values of GPS-MBA, MHC2Pred and RANKPEP were 62.89%, 23.58%, and 33.65%, respectively (Table 2). Also, when the Sp value was ∼95%, the Sn values of GPS-MBA, MHC2Pred and RANKPEP were 71.70%, 32.70%, and 45.91%, respectively (Table 2). Furthermore, when the Sp value was ∼90%, the Sn of GPS-MBA (84.91%) was still much better than MHC2Pred (47.80%) and RANKPEP (64.15%) (Table 2). Once again, for HLA-DQ8, the GPS-MBA performance is still much better than the other two predictors. In addition, ROC curves were drawn, showing that the AROC values of the GPS-MBA were generally better than the other approaches to I-Ag7 (Figure 3C) and HLA-DQ8 (Figure 3D).
Previous experimental studies suggested that the mouse I-Ag7 haplotype is equivalent to the human HLA-DQ8 linkage, and exhibits a similar specificity for peptide recognition and binding –, –. To investigate this viewpoint, we performed a cross-evaluation using the HLA-DQ8 predictor in GPS-MBA to predict I-Ag7 epitopes (Figure 3C) and vice versa (Figure 3D). In our results, the cross-evaluation performance is closely similar to the LOO validations (Figure 3C, 3D, and Table 2). Thus, we propose that the binding patterns of I-Ag7 and HLA-DQ8 are highly similar and conserved.
Prediction of potentially new I-Ag7 and HLA-DQ8 epitopes in T1D
Besides I-Ag7 and HLA-DQ8, certain other MHC class I and II molecules are also implicated in T1D –, –. We collected 203 epitopes in 25 proteins from the scientific literature, with 70 MHC class I epitopes, 84 MHC class II binding peptides and 49 epitopes for which the MHC molecules are still undetermined (Table 3, Table S3). Although at present there is a lack of experimental verification, we propose that a number of these epitopes will also come to be recognized by I-Ag7 and/or HLA-DQ8.
To predict potential I-Ag7 and HLA-DQ8 epitopes, we used GPS-MBA 1.0 with the default thresholds. In total, 68 epitopes were predicted to interact with either I-Ag7 or HLA-DQ8 (33.5%) (Table 3). Also, the prediction results of MHC2Pred ,  and RANKPEP  were present with default thresholds (Table 3). In particular, the prediction performance of GPS-MBA 1.0 is much poorer in terms of the MHC class I epitopes, such that only one and three epitopes were predicted as I-Ag7 and HLA-DQ8 binding peptides, respectively (Table 3). However, GPS-MBA 1.0 displayed a considerably effective performance for MHC class II epitopes by predicting 31 I-Ag7 and 28 HLA-DQ8 binding peptides (Table 3). Also, the distributions of results from MHC2Pred and RANKPEP are similar (Table 3). In this regard, the sequence profiles of MHC class I and II are quite different, whereas GPS-MBA, MHC2Pred and RANKPEP have the capacity to efficiently distinguish both MHC class I and II epitopes. In particular, GPS-MBA, MHC2Pred and RANKPEP predicted 28 (57.14%), 29 (59.18%) and 33 (67.35%) unannotated epitopes as having either I-Ag7 or HLA-DQ8 binding peptides (Table 3). Taken together, this analysis suggests that there are additional bona fide I-Ag7 and HLA-DQ8 epitopes which still remain to be identified, and these prediction results comprise a useful resource for further experimental investigation. The detailed prediction results of GPS-MBA are shown in Table S1.
The development and usage of TEDB 1.0
To provide an integrative platform for computational analysis of the T1D epitopes, all of the experimental identified T1D-associated antigens together with their epitopes were collected for the development of TEDB (Table 4). Also, we used GPS-MBA 1.0 at the default threshold to predict potential I-Ag7 or HLA-DQ8 epitopes in 245 antigens (Table 4). In addition, the prediction results of MHC2Pred and RANKPEP were also included in the TEDB 1.0.
TEDB 1.0 was developed in a user-friendly manner. The search option (http://mba.biocuckoo.org/database.php) provides an interface for querying the TEDB database with one or several keywords such as TEDB ID, MHC Type, or UniProt Accession, etc (Figure 4A). We also provided three advance options, including advance search, browse and BLAST search (Figure 4A). For example, if the keyword ‘RAN’ is inputted and submitted (Figure 4A), the result is shown in a tabular format, with the features of TEDB ID, UniProt accession, and protein/gene names/aliases (Figure 4B). By clicking on the TEDB ID (TEDB-HS-00015), the detailed information on human RAN is shown (Figure 4C). The experimentally identified epitopes and predicted I-Ag7 and HLA-DQ8 binding peptides are provided, while the protein sequence, Gene Ontology annotation, domain organization, molecular weight and computed/theoretical Ip are also provided (Figure 4C).
(A) Users are able to simply input ‘RAN’ and select “Gene Name” for querying. (B) The results are shown in a tabular format. Users can then click on the TEDB ID (TEDB-HS-00015) to visualize the detailed information. (C) The detailed information on human RAN. The experimentally identified and predicted epitopes are presented.
T1D, also termed Insulin-dependent diabetes mellitus (IDDM) or juvenile diabetes, is a chronic metabolic disorder and autoimmune disease that takes a heavy toll world-wide –, . Currently, it is estimated that approximately 70,000 children develop T1D per year, ∼30,000 of which cases are in the United States, and an annual global increase of ∼3% , , . Although a number of immunotherapeutic and regenerative approaches have been developed, the effective prevention and treatment of T1D are both still a great challenge –, . Recent advances in the development of antigen-based “tolerogenic” immunotherapy have provided a great opportunity for treating T1D with a high degree of selectivity, while two investigations are still ongoing as clinical trials, and the outcome is uncertain –, , . In this regard, the Identification of T1D-speicific epitopes is needed for further experimental and biomedical design.
Although a number of computational analyses were carried out for the prediction of the I-Ag7 or HLA-DQ8 epitopes, the online services have been not available over the internet –. Again, although the two integrative tools of MHC2Pred and RANKPEP do contain predictors of I-Ag7 and HLA-DQ8, they were actually designed for the general prediction of MHC class I and/or II epitopes –. Thus, they might exhibit a sensitive performance for other MHC molecules, and yet not I-Ag7 and/or HLA-DQ8. In this study, we focused on the prediction of I-Ag7 and HLA-DQ8 by constructing the GPS-MBA software package. By comparison, the performance of GPS-MBA is much better than MHC2Pred and RANKPEP (Table 2, Figure 3C, 3D).
Originally, the series of GPS algorithms were developed for the prediction of PTM sites in proteins , , and this is the first use of the algorithm for MHC epitopes. The major difference between PTM sites and MHC epitopes is that the PTM site positions are anchored by the middle residues, while the lengths and positions of the MHC epitopes are promiscuous and difficult to fix. In this regard, the MHC epitope core sequences of defined length must be determined prior to training. Originally, the Gibbs sampling method was designed for detecting short conserved motifs from multiple DNA or protein sequences –. By utilizing the position-specific scoring matrices (PSSMs), the amino acids frequencies were counted in the foreground and background data sets, respectively. In this procedure, the ratio of the pattern probability to the background probability was calculated and improved by sampling, until convergence was attained –. However, the average similarity score, but not the frequency ratio, was calculated for further sampling in our analysis. The 9-mer core peptides were determined by this approach for I-Ag7 and HLA-DQ8, respectively.
Here, we used the WebLogo server  to analyze the sequence profiles of the core nonamers for I-Ag7 (Figure 5A) and HLA-DQ8 (Figure 5B), respectively. Previously, experimental studies based on limited epitopes had suggested that P4, P6 and P9 are three conserved positions, while P1 is a degenerate position –. However, our results suggest that P9 is the most informative position, along with a less the comparatively weakly conserved position of P8 (Figure 5A, 5B). P4 is weakly conserved in I-Ag7 core nonamers (Figure 5A) and not conserved in HLA-DQ8 (Figure 5B). Although the sequence logo of I-Ag7 is not evidently similar to HLA-DQ8, our cross-evaluation results indicate that I-Ag7 and HLA-DQ8 are able to recognize similar peptide profiles (Table 2, Figure 3C, 3D). We speculated that whether most of the HLA-DQ8 epitopes would also be I-Ag7 binding peptides in the training data set, since the NOD mouse is the best model for T1D. However, there are only 24 epitopes in the original data set which interact with both I-Ag7 (24/318) and HLA-DQ8 (24/134). Again, in the non-redundant core nonamers, only 22 9-mer peptides were found to bind with both I-Ag7 and HLA-DQ8. Based on these results, we propose that the sequence profile of I-Ag7 is intrinsically similar to that of HLA-DQ8.
In addition to the predictions of GPS-MBA, all of the experimentally validated T1D-associated epitopes were collected in the online database of TEDB 1.0. The ab initio predictions with GPS-MBA were also integrated into TEDB. Thus, such an integrative platform should prove to be useful for experimentalists. We believe that computational analysis, together with subsequent experimental identification, will help advance the study of T1D into a new and highly productive phase.
The core nonamers of the mouse I-Ag7 epitopes. a. Epitope, the original epitopes; b. Position, the positions of core nonamers in the protein sequences; c. Core nonamer, the finally aligned core nonamers were marked in red; d. The protein sequence was retrieved from the UniParc (UniProt Archive) Database (http://www.uniprot.org/help/uniparc).
The core nonamers of the human HLA-DQ8 epitopes.
From the scientific literature, we collected 203 epitopes in 25 proteins, with 70 MHC class I epitopes, 84 MHC class II binding peptides, and 49 epitopes for which the MHC molecules are still unknown. The detailed prediction results of GPS-ARM were provided. a. UniProt, the UniProt accession numbers of T1D antigens; b. Pos., the position of the original known epitopes; c. Peptide, the experimentally identified epitopes; d. MHC Type, the experimentally identified MHC molecules that recognize the epitopes; e. Pre. Pos., the predicted position of the binding peptides; f. Pre. Peptide, the predicted core nonamers; g. Pre. Type, the predicted MHC molecules of I-Ag7 and HLA-DQ8 that potentially recognize the core 9-mers.
The authors are thankful for two anonymous reviewers, whose suggestions have greatly improved the presentation of this manuscript. Pacific Edit reviewed the manuscript prior to submission.
Conceived and designed the experiments: YX QY RC ZL. Performed the experiments: RC ZL QY YX. Analyzed the data: RC ZL QY YX. Contributed reagents/materials/analysis tools: JR CM TG YZ. Wrote the paper: YX QY ZL RC.
- 1. Fierabracci A (2011) Peptide immunotherapies in Type 1 diabetes: lessons from animal models. Curr Med Chem 18: 577–586.A. Fierabracci2011Peptide immunotherapies in Type 1 diabetes: lessons from animal models.Curr Med Chem18577586
- 2. Luo X, Herold KC, Miller SD (2010) Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 32: 488–499.X. LuoKC HeroldSD Miller2010Immunotherapy of type 1 diabetes: where are we and where should we be going?Immunity32488499
- 3. Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464: 1293–1300.JA BluestoneK. HeroldG. Eisenbarth2010Genetics, pathogenesis and clinical interventions in type 1 diabetes.Nature46412931300
- 4. Sherr J, Sosenko J, Skyler JS, Herold KC (2008) Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab 4: 334–343.J. SherrJ. SosenkoJS SkylerKC Herold2008Prevention of type 1 diabetes: the time has come.Nat Clin Pract Endocrinol Metab4334343
- 5. Waldron-Lynch F, Herold KC (2011) Immunomodulatory therapy to preserve pancreatic beta-cell function in type 1 diabetes. Nat Rev Drug Discov 10: 439–452.F. Waldron-LynchKC Herold2011Immunomodulatory therapy to preserve pancreatic beta-cell function in type 1 diabetes.Nat Rev Drug Discov10439452
- 6. Panagiotopoulos C, Trudeau JD, Tan R (2004) T-cell epitopes in type 1 diabetes. Curr Diab Rep 4: 87–94.C. PanagiotopoulosJD TrudeauR. Tan2004T-cell epitopes in type 1 diabetes.Curr Diab Rep48794
- 7. von Herrath M, Sanda S, Herold K (2007) Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 7: 988–994.M. von HerrathS. SandaK. Herold2007Type 1 diabetes as a relapsing-remitting disease?Nat Rev Immunol7988994
- 8. Lehuen A, Diana J, Zaccone P, Cooke A (2010) Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 10: 501–513.A. LehuenJ. DianaP. ZacconeA. Cooke2010Immune cell crosstalk in type 1 diabetes.Nat Rev Immunol10501513
- 9. Reizis B, Eisenstein M, Bockova J, KonenWaisman S, Mor F, et al. (1997) Molecular characterization of the diabetes-associated mouse MHC class II protein, I-A(g7). International Immunology 9: 43–51.B. ReizisM. EisensteinJ. BockovaS. KonenWaismanF. Mor1997Molecular characterization of the diabetes-associated mouse MHC class II protein, I-A(g7).International Immunology94351
- 10. Harrison LC, Honeyman MC, Trembleau S, Gregori S, Gallazzi F, et al. (1997) A peptide-binding motif for I-A(g7), the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H mice. J Exp Med 185: 1013–1021.LC HarrisonMC HoneymanS. TrembleauS. GregoriF. Gallazzi1997A peptide-binding motif for I-A(g7), the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H mice.J Exp Med18510131021
- 11. Suri A, Walters JJ, Gross ML, Unanue ER (2005) Natural peptides selected by diabetogenic DQ8 and murine I-A(g7)molecules show common sequence specificity. Journal of Clinical Investigation 115: 2268–2276.A. SuriJJ WaltersML GrossER Unanue2005Natural peptides selected by diabetogenic DQ8 and murine I-A(g7)molecules show common sequence specificity.Journal of Clinical Investigation11522682276
- 12. Tong JC, Tan TW, Ranganathan S (2007) Methods and protocols for prediction of immunogenic epitopes. Brief Bioinform 8: 96–108.JC TongTW TanS. Ranganathan2007Methods and protocols for prediction of immunogenic epitopes.Brief Bioinform896108
- 13. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr (1991) Sequence analysis of peptides bound to MHC class II molecules. Nature 353: 622–627.A. RudenskyP. Preston-HurlburtSC HongA. BarlowCA Janeway Jr1991Sequence analysis of peptides bound to MHC class II molecules.Nature353622627
- 14. Sette A, Buus S, Appella E, Smith JA, Chesnut R, et al. (1989) Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A 86: 3296–3300.A. SetteS. BuusE. AppellaJA SmithR. Chesnut1989Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis.Proc Natl Acad Sci U S A8632963300
- 15. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213–219.H. RammenseeJ. BachmannNP EmmerichOA BachorS. Stevanovic1999SYFPEITHI: database for MHC ligands and peptide motifs.Immunogenetics50213219
- 16. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152: 163–175.KC ParkerMA BednarekJE Coligan1994Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.J Immunol152163175
- 17. Reche PA, Reinherz EL (2007) Prediction of peptide-MHC binding using profiles. Methods Mol Biol 409: 185–200.PA RecheEL Reinherz2007Prediction of peptide-MHC binding using profiles.Methods Mol Biol409185200
- 18. Bhasin M, Raghava GP (2004) SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence. Bioinformatics 20: 421–423.M. BhasinGP Raghava2004SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence.Bioinformatics20421423
- 19. Culina S, Boitard C, Mallone R (2011) Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks? Clin Dev Immunol 2011: 286248.S. CulinaC. BoitardR. Mallone2011Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?Clin Dev Immunol2011286248
- 20. Rajapakse M, Zhang GL, Srinivasan KN, Schmidt B, Petrovsky N, et al. (2006) PREDNOD, a prediction server for peptide binding to the H-2g7 haplotype of the non-obese diabetic mouse. Autoimmunity 39: 645–650.M. RajapakseGL ZhangKN SrinivasanB. SchmidtN. Petrovsky2006PREDNOD, a prediction server for peptide binding to the H-2g7 haplotype of the non-obese diabetic mouse.Autoimmunity39645650
- 21. Chang KY, Suri A, Unanue ER (2007) Predicting peptides bound to I-Ag7 class II histocompatibility molecules using a novel expectation-maximization alignment algorithm. Proteomics 7: 367–377.KY ChangA. SuriER Unanue2007Predicting peptides bound to I-Ag7 class II histocompatibility molecules using a novel expectation-maximization alignment algorithm.Proteomics7367377
- 22. Chang KY, Unanue ER (2009) Prediction of HLA-DQ8beta cell peptidome using a computational program and its relationship to autoreactive T cells. Int Immunol 21: 705–713.KY ChangER Unanue2009Prediction of HLA-DQ8beta cell peptidome using a computational program and its relationship to autoreactive T cells.Int Immunol21705713
- 23. Rajapakse M, Schmidt B, Feng L, Brusic V (2007) Predicting peptides binding to MHC class II molecules using multi-objective evolutionary algorithms. BMC Bioinformatics 8: 459.M. RajapakseB. SchmidtL. FengV. Brusic2007Predicting peptides binding to MHC class II molecules using multi-objective evolutionary algorithms.BMC Bioinformatics8459
- 24. Bhasin M, Raghava GPS (2004) SVM based method for predicting HLA-DRB1(*)0401 binding peptides in an antigen sequence. Bioinformatics 20: 421–423.M. BhasinGPS Raghava2004SVM based method for predicting HLA-DRB1(*)0401 binding peptides in an antigen sequence.Bioinformatics20421423
- 25. Lata S, Bhasin M, Raghava GP (2007) Application of machine learning techniques in predicting MHC binders. Methods Mol Biol 409: 201–215.S. LataM. BhasinGP Raghava2007Application of machine learning techniques in predicting MHC binders.Methods Mol Biol409201215
- 26. Lundegaard C, Lund O, Nielsen M (2008) Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24: 1397–1398.C. LundegaardO. LundM. Nielsen2008Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers.Bioinformatics2413971398
- 27. Liu Z, Cao J, Gao X, Ma Q, Ren J, et al. (2011) GPS-CCD: a novel computational program for the prediction of calpain cleavage sites. PLoS One 6: e19001.Z. LiuJ. CaoX. GaoQ. MaJ. Ren2011GPS-CCD: a novel computational program for the prediction of calpain cleavage sites.PLoS One6e19001
- 28. Xue Y, Liu Z, Gao X, Jin C, Wen L, et al. (2010) GPS-SNO: computational prediction of protein S-nitrosylation sites with a modified GPS algorithm. PLoS One 5: e11290.Y. XueZ. LiuX. GaoC. JinL. Wen2010GPS-SNO: computational prediction of protein S-nitrosylation sites with a modified GPS algorithm.PLoS One5e11290
- 29. Lawrence CE, Altschul SF, Boguski MS, Liu JS, Neuwald AF, et al. (1993) Detecting subtle sequence signals: a Gibbs sampling strategy for multiple alignment. Science 262: 208–214.CE LawrenceSF AltschulMS BoguskiJS LiuAF Neuwald1993Detecting subtle sequence signals: a Gibbs sampling strategy for multiple alignment.Science262208214
- 30. Neuwald AF, Liu JS, Lawrence CE (1995) Gibbs motif sampling: detection of bacterial outer membrane protein repeats. Protein Sci 4: 1618–1632.AF NeuwaldJS LiuCE Lawrence1995Gibbs motif sampling: detection of bacterial outer membrane protein repeats.Protein Sci416181632
- 31. Nielsen M, Lundegaard C, Worning P, Hvid CS, Lamberth K, et al. (2004) Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics 20: 1388–1397.M. NielsenC. LundegaardP. WorningCS HvidK. Lamberth2004Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach.Bioinformatics2013881397
- 32. Suri A, Vidavsky I, van der Drift K, Kanagawa O, Gross ML, et al. (2002) In APCs, the autologous peptides selected by the diabetogenic I-Ag7 molecule are unique and determined by the amino acid changes in the P9 pocket. J Immunol 168: 1235–1243.A. SuriI. VidavskyK. van der DriftO. KanagawaML Gross2002In APCs, the autologous peptides selected by the diabetogenic I-Ag7 molecule are unique and determined by the amino acid changes in the P9 pocket.J Immunol16812351243
- 33. Burn P (2010) Type 1 diabetes. Nat Rev Drug Discov 9: 187–188.P. Burn2010Type 1 diabetes.Nat Rev Drug Discov9187188
- 34. Crooks GE, Hon G, Chandonia JM, Brenner SE (2004) WebLogo: a sequence logo generator. Genome Res 14: 1188–1190.GE CrooksG. HonJM ChandoniaSE Brenner2004WebLogo: a sequence logo generator.Genome Res1411881190